Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

A crystalline form of the compound of Formula 1, or a pharmaceutical acceptably salt thereof:

• wherein the crystalline form is designated as a Form A, a Form B, a Form C, or a Form D;
• wherein the Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising characteristic peaks at diffraction angles 2θ of approximately 5.9°, 11.9°, and 25.6°;
• wherein the Form B is characterized by an X-ray powder diffraction pattern comprising any three (3) of characteristic any three (3) of peaks at diffraction angles 2° of approximately 4.7°, 11.2°, 14.1°, 15.3° and 21.2°;
• wherein the Form C is characterized by an X-ray powder diffraction pattern comprising characteristic peaks at diffraction angles 2θ of approximately 6.4°, 12.8° and 20.7°;
• and
• wherein the Form D, is characterized by an X-ray powder diffraction pattern comprising any three (3) of characteristic peaks at diffraction angles 2θ of approximately 4.8°, 8.3°, 10.5°, 11.5°, and 14.0°.